WCM Investment Management LLC Sells 2,072 Shares of Repligen Co. (NASDAQ:RGEN)

WCM Investment Management LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 97,086 shares of the biotechnology company's stock after selling 2,072 shares during the period. WCM Investment Management LLC owned approximately 0.17% of Repligen worth $13,962,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its position in Repligen by 46.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,629 shares of the biotechnology company's stock valued at $2,679,000 after purchasing an additional 5,913 shares in the last quarter. Alliance Wealth Advisors LLC UT grew its stake in shares of Repligen by 5.9% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 3,586 shares of the biotechnology company's stock valued at $516,000 after buying an additional 199 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in shares of Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after buying an additional 6,872 shares during the last quarter. Slow Capital Inc. grew its stake in shares of Repligen by 3.3% during the fourth quarter. Slow Capital Inc. now owns 16,760 shares of the biotechnology company's stock valued at $2,412,000 after buying an additional 534 shares during the last quarter. Finally, Ballentine Partners LLC grew its stake in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock valued at $270,000 after buying an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on RGEN shares. HC Wainwright reduced their price objective on Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, January 3rd. Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Finally, TD Cowen began coverage on shares of Repligen in a report on Monday. They issued a "buy" rating and a $200.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and a consensus target price of $186.00.

Repligen Stock Up 0.3 %

Shares of RGEN stock traded up $0.45 during trading hours on Thursday, hitting $146.17. 519,443 shares of the company's stock traded hands, compared to its average volume of 552,770. The stock's fifty day simple moving average is $155.39 and its two-hundred day simple moving average is $149.11. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The stock has a market cap of $8.19 billion, a price-to-earnings ratio of -395.04, a PEG ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the business earned $0.23 EPS. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. On average, analysts expect that Repligen Co. will post 1.54 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.